Latest On Reata Pharmaceuticals, Inc (RETA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-24 21:07 EST | News | Reata adds 21% as PTC’s Friedreich's ataxia drug fails Phase 3 trial | N/A |  |
| 2023-05-23 16:54 EST | News | Reata Pharmaceuticals: 'Buy' Following Skyclarys Delay And Bardoxolone Discontinuation (Rating Upgrade) | N/A | |
| 2023-05-11 09:45 EST | News | Reata Pharmaceuticals, Inc. (RETA) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-10 19:51 EST | News | Reata Pharmaceuticals Non-GAAP EPS of -$1.81 in-line, revenue of $0.2M beats by $0.04M | N/A | |
| 2023-05-10 19:51 EST | News | Reata sheds 18% after halting kidney disease programs | N/A | |
About Reata Pharmaceuticals, Inc (RETA):
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also dev read more...eloping RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
General
- Name Reata Pharmaceuticals, Inc
- Symbol RETA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 261
- Fiscal Year EndDecember
- IPO Date2016-05-26
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.reatapharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 485.33
- Price/Book (Most Recent Quarter) 11.26
- Enterprise Value Revenue 430.48
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$9.89
- Next Year EPS Estimate -$6.39
- Next Quarter EPS Estimate -$2.17
- Operating Margin -2509%
- Return on Assets -18%
- Return on Equity -73%
- Revenue 9.02 million
- Earnings Per Share -$4.06
- Revenue Per Share $0.27
- Gross Profit -150061000
- Quarterly Earnings Growth 19.5%
Highlights
- Market Capitalization 4.26 billion
- EBITDA -116066000
- PE Ratio -15.52
- Analyst Target Price $243.38
- Book Value Per Share $11.55
Share Statistics
- Shares Outstanding 31.29 million
- Shares Float 29.87 million
- % Held by Insiders 477%
- % Held by Institutions 71.49%
- Shares Short 3.31 million
- Shares Short Prior Month 3.29 million
- Short Ratio 12.31
- Short % of Float 14%
- Short % of Shares Outstanding 9%
Technicals
- Beta 1.62
- 52 Week High $186.82
- 52 Week Low $88.17
- 50 Day Moving Average 120.08
- 200 Day Moving Average 122.14
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Reata Pharmaceuticals, Inc (RETA) Dividend Calendar:
Reata Pharmaceuticals, Inc (RETA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Reata Pharmaceuticals, Inc (RETA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Reata Pharmaceuticals, Inc (RETA) Chart:
Reata Pharmaceuticals, Inc (RETA) News:
Below you will find a list of latest news for Reata Pharmaceuticals, Inc (RETA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Reata Pharmaceuticals, Inc (RETA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest RETA Trades:
Reata Pharmaceuticals, Inc (RETA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-09 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-27 | 8-K (Current report) | |
| 2020-08-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-04 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-31 | 8-K (Current report) | |
| 2020-07-07 | 8-K (Current report) | |
| 2020-06-25 | D (Notice of Exempt Offering of Securities) | |
| 2020-06-25 | D (Notice of Exempt Offering of Securities) | |
| 2020-06-24 | 8-K (Current report) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-11 | 8-K (Current report) | |
| 2020-06-11 | 8-K (Current report) | |
| 2020-06-02 | 8-K (Current report) | |
Reata Pharmaceuticals, Inc (RETA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Reata Pharmaceuticals, Inc (RETA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 477%
Institutional Ownership: 7149%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-14 | Manmeet Singh Soni | COO and CFO | Buy | 2,000.00 | 100.22 | 200,440.00 | 2,000.00 | |
| 2020-08-14 | Manmeet Singh Soni | COO and CFO | Buy | 1,000.00 | 100.19 | 100,190.00 | 3,000.00 | |
| 2020-06-01 | Elaine Castellanos | VP, Chief Accounting Officer | Sell | 2,000.00 | 143.97 | 287,940.00 | 15,146.00 | |
| 2020-03-02 | Elaine Castellanos | VP, Chief Accounting Officer | Sell | 2,000.00 | 194.32 | 388,640.00 | 15,146.00 | |
| 2019-12-16 | Jason Douglas Wilson | Executive VP of Operations | Sell | 400.00 | 207.48 | 82,992.00 | 12,950.00 | |
| 2019-12-16 | Jason Douglas Wilson | Executive VP of Operations | Sell | 400.00 | 206.89 | 82,754.00 | 13,350.00 | |
| 2019-12-16 | Jason Douglas Wilson | Executive VP of Operations | Sell | 200.00 | 205.08 | 41,015.00 | 13,750.00 | |
| 2019-12-16 | Jason Douglas Wilson | Executive VP of Operations | Sell | 1,480.00 | 204.54 | 302,722.16 | 13,950.00 | |
| 2019-12-16 | Jason Douglas Wilson | Executive VP of Operations | Sell | 2,320.00 | 203.60 | 472,342.26 | 15,430.00 | |
| 2019-12-16 | Jason Douglas Wilson | Executive VP of Operations | Sell | 3,400.00 | 202.51 | 688,534.00 | 17,750.00 | |
| 2019-12-16 | Jason Douglas Wilson | Executive VP of Operations | Sell | 1,300.00 | 201.65 | 262,145.52 | 21,150.00 | |
| 2019-12-16 | Jason Douglas Wilson | Executive VP of Operations | Sell | 500.00 | 200.17 | 100,086.40 | 22,450.00 | |
| 2019-12-02 | Elaine Castellanos | VP, Chief Accounting Officer | Sell | 2,000.00 | 194.24 | 388,480.00 | 15,146.00 | |
| 2019-11-20 | WILLIAM ROSE | Director | Sell | 2,000.00 | 215.32 | 430,640.00 | 19,795.00 | |
| 2019-11-20 | WILLIAM ROSE | Director | Sell | 2,000.00 | 211.27 | 422,540.00 | 21,795.00 | |
| 2019-11-20 | WILLIAM ROSE | Director | Sell | 2,000.00 | 210.00 | 420,000.00 | 23,795.00 | |
| 2019-11-20 | WILLIAM ROSE | Director | Sell | 591.00 | 215.89 | 127,590.99 | 25,795.00 | |
| 2019-11-19 | WILLIAM ROSE | Director | Sell | 2,000.00 | 210.00 | 420,000.00 | 26,386.00 | |
| 2019-11-18 | CPMG Inc | Director | Buy | 7,104.00 | 183.00 | 1,300,032.00 | 116,512.00 | |
| 2019-11-18 | CPMG Inc | Director | Buy | 27,322.00 | 183.00 | 4,999,926.00 | 137,962.00 | |